Kamada, Chiesi Farmaceutici Terminate Inhaled Alpha-1 Antitrypsin Therapy Deal Post author:Sam Post published:November 19, 2017 Post category:BioPharma Kamada now maintains full, worldwide commercial rights to its inhaled AAT. Source: BioSpace You Might Also Like Novartis AG to Shed Another 500 Jobs, Add 350 High-Tech Jobs May 18, 2017 Biotech Startup Quietly Sets Up Shop in Maryland July 13, 2017 Alere Coughs Up $13 Million to Settle Accounting Fraud Charges With the September 28, 2017
